{
Jo Walton

People

}
Very Negative
Negative
Neutral
Positive
Very Positive
2025-03-312025-03-311111100
Download SVG
Download PNG
Download CSV
Somewhat Relevant
Moderately Relevant
Very Relevant
Highly Relevant
2025-03-312025-03-311111100
Download SVG
Download PNG
Download CSV

ubs raises sanofi target price to 120 euros maintains buy rating

UBS has increased its target price for Sanofi from 115 to 120 euros while maintaining a "Buy" rating, citing a strong fourth quarter and an impressive share buyback program. Analyst Jo Walton noted high single-digit growth for Dupixent and expressed confidence in the respiratory drug Beyfortus despite competition.
boerse.de
Euro Sanofi FRA Jo Walton
Finance & Economy, Market Report
11:20 31.01.2025

ubs raises sanofi target price to 120 euros maintaining buy rating

UBS has raised its target price for Sanofi from 115 to 120 euros, maintaining a "Buy" rating. Analyst Jo Walton noted a strong fourth quarter and an impressive share buyback program, with Dupixent continuing to show high single-digit growth. The company remains optimistic about its respiratory drug Beyfortus despite competition.
MarketScreener
Euro Sanofi FRA Jo Walton
Finance & Economy, Market Report
11:07 31.01.2025

ubs raises sanofi target price to 120 euros maintaining buy rating

UBS has increased its target price for Sanofi from 115 to 120 euros, maintaining a "Buy" rating. Analyst Jo Walton noted a strong fourth quarter and an impressive share buyback program, while highlighting the continued growth of the drug Dupixent and confidence in the respiratory drug Beyfortus despite competition.
aktiencheck.de
Euro Sanofi FRA Jo Walton
Finance & Economy, Market Report
10:20 31.01.2025

UBS maintains neutral rating for GlaxoSmithKline with cautious 2025 outlook

UBS has maintained a "Neutral" rating for GlaxoSmithKline (GSK) with a target price of 1580 pence. Analyst Jo Walton anticipates a cautious outlook from GSK for 2025, while expecting the company to reaffirm its targets for 2030 during the upcoming reporting season.
boerse.de
British Pound Sterling GLAXOSMITHKLINE CAPITAL PLC 4.0 GBR Jo Walton
Finance & Economy, Market Report
13:10 30.01.2025

UBS maintains buy rating for Sanofi with target price of 115 euros

UBS has maintained its "Buy" rating for Sanofi, setting a target price of 115 euros. Analyst Jo Walton positively assessed the company's quarterly report, noting that the share buyback program exceeded expectations.
boerse.de
Euro Sanofi CHE FRA Warren Buffett Hubert Dichtl Jo Walton Thomas Müller Show more
Finance & Economy, Market Report
12:43 30.01.2025

ubs maintains buy rating for sanofi with target price of 115 euros

UBS has maintained a 'Buy' rating for Sanofi, setting a target price of 115 euros. Analyst Jo Walton positively assessed the company's quarterly report, noting that the share buyback program exceeded expectations. As of the latest trading, Sanofi shares are priced at approximately 103.12 euros, reflecting a 1.38% increase.
aktiencheck.de
Euro Sanofi FRA Jo Walton
Finance & Economy, Market Report
11:43 30.01.2025

UBS maintains buy rating for Novo Nordisk with target price of 750 crowns

UBS has maintained a 'Buy' rating for Novo Nordisk, setting a target price of 750 Danish crowns ahead of the fourth quarter results. Analyst Jo Walton noted that expectations are low, with particular attention on the drugs CagriSema and Amycretin, as well as the company's future plans. Novo Nordisk has seen a remarkable 3,501% increase since its initial recommendation.
boerse.de
Danish Krone Novo Nordisk A/S DNK Jo Walton
Finance & Economy, Market Report
19:09 29.01.2025

UBS maintains buy rating for Sanofi with target price of 115 euros

UBS has maintained a "Buy" rating for Sanofi, setting a target price of 115 euros. Analyst Jo Walton highlights the stock's attractiveness in the European pharmaceutical sector, noting it is trading at a significant discount compared to peers. Anticipation builds for share buyback announcements at the end of January.
boerse.de
Euro Sanofi FRA CHE Warren Buffett Hubert Dichtl Jo Walton Thomas Müller Show more
Finance & Economy, Market Report
09:41 23.01.2025

ubs maintains buy rating for sanofi with target price of 115 euros

UBS has maintained a 'Buy' rating for Sanofi, setting a target price of 115 euros. Analyst Jo Walton views Sanofi's stock as highly attractive within the European pharmaceutical sector as it trades at a significant discount compared to peers, anticipating share buyback announcements at the end of January.
MarketScreener
Euro Sanofi FRA CHE Jo Walton
Finance & Economy, Market Report
09:27 23.01.2025

ubs maintains buy rating for novo nordisk with target price of 750 crowns

UBS has maintained its "Buy" rating for Novo Nordisk, setting a target price of 750 Danish crowns. Analyst Jo Walton noted that rival Eli Lilly's weight-loss injection, Zepbound, has seen a stronger recovery in prescriptions compared to Novo's Wegovy following the Christmas period.
boerse.de
Danish Krone Novo Nordisk A/S Eli Lilly and Company DNK Jo Walton
Finance & Economy, Market Report
08:15 21.01.2025
Trending
Subcategory
Stock Market Updates Corporate News Industry Trends Global Trade Developments Global Financial Events Banking Regulations Retail and Consumer Goods Startups & Entrepreneurship Central Bank Actions Finance Mergers & Acquisitions Industry Mergers & Acquisitions Inflation and Monetary Impact Government Economic Policies CEO Changes Market Analysis and Predictions Domestic Politics Government Policies Workplace Trends GDP Growth & Recession Forecasts Financial Scams and Security
Countries:
USA CHN GBR CHE IND DEU JPN FRA CAN VNM ARE ESP MEX ITA SGP AUS TWN THA MYS IDN
Companies:
Tesla, Inc. Apple Inc. Barclays PLC JPMorgan Chase & Co. Deutsche Bank Money Market PP The Goldman Sachs Group, Inc. Credit Suisse Strategic Income I Banco Santander, S.A. Berkshire Hathaway Inc. SpaceXCoin USD Bank of America Corporation Morgan Stanley BNP Paribas SA Amazon.com, Inc. UBS Group AG Lloyds Banking Group plc NVIDIA Corporation Bank Frick AG Citigroup Inc. Wells Fargo & Company
Currencies:
United States Dollar Euro British Pound Sterling Japanese Yen Swiss Franc Indian Rupee Chinese Yuan South Korean Won Vietnamese Đồng Canadian Dollar Australian Dollar Thai Baht Indonesian Rupiah Singapore Dollar Mexican Peso New Taiwan Dollar Russian Ruble Hong Kong Dollar Offshore Chinese Yuan New Zealand Dollar
People:
Donald Trump Elon Musk JD Vance Warren Buffett Sergio Ermotti Mark Haefele Jennifer Piepszak Karoline Leavitt Ursula von der Leyen Olivier Calvet Scott Bessent George Saravelos Francois Xavier Bouvignies Joseph Spak Robin Leopold Stefan Rauti Susan P. Crawford Greg Rubini Dan Ives Savio D'souza

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.